<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Doses of selective serotonin reuptake inhibitors used in the treatment of obsessive-compulsive disorder in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Doses of selective serotonin reuptake inhibitors used in the treatment of obsessive-compulsive disorder in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Doses of selective serotonin reuptake inhibitors used in the treatment of obsessive-compulsive disorder in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">SSRI</td> <td class="subtitle1">Usual starting dose per day (mg)</td> <td class="subtitle1">Dose titration increments based upon response (mg)*</td> <td class="subtitle1">Therapeutic dose range for OCD (mg/day)</td> <td class="subtitle1">Supratherapeutic dose range (mg/day)</td> </tr> <tr> <td>Citalopram</td> <td class="centered">20</td> <td class="centered">10 to 20</td> <td class="centered">40 to 60<sup>¶</sup></td> <td class="centered">Not recommended<sup>Δ</sup></td> </tr> <tr> <td>Escitalopram</td> <td class="centered">10</td> <td class="centered">10</td> <td class="centered">20 to 40</td> <td class="centered">60</td> </tr> <tr> <td>Fluoxetine</td> <td class="centered">20</td> <td class="centered">20</td> <td class="centered">40 to 80</td> <td class="centered">120</td> </tr> <tr> <td>Fluvoxamine<sup>◊</sup></td> <td class="centered">50</td> <td class="centered">50</td> <td class="centered">200 to 300</td> <td class="centered">400</td> </tr> <tr> <td>Fluvoxamine CR</td> <td class="centered">100</td> <td class="centered">50</td> <td class="centered">200 to 300</td> <td class="centered">400</td> </tr> <tr> <td>Paroxetine</td> <td class="centered">20</td> <td class="centered">10 to 20</td> <td class="centered">40 to 60</td> <td class="centered">100</td> </tr> <tr> <td>Sertraline</td> <td class="centered">50</td> <td class="centered">25 to 50</td> <td class="centered">200 to 300</td> <td class="centered">400</td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>NOTE: Lower doses may be useful for initiating or maintaining patients who are older or medically compromised (eg, heart failure, kidney or liver disease), or patients known to be sensitive to drug side-effects, as well as patients with a low body mass index. Extreme daily doses may be used for medications that are well tolerated but ineffective at lower doses.</p>
For agent selection including considerations related to adverse effect profiles, refer to UpToDate clinical topic and separately available table of antidepressant adverse effects. For dose adjustments for drug interactions and other factors, refer to Lexicomp drug monographs included within UpToDate.</div><div class="graphic_footnotes"><p>SSRI: selective serotonin reuptake inhibitor; OCD: obsessive-compulsive disorder.</p>
<p>* UpToDate typically titrates to maximum tolerated dose within therapeutic dose range at weekly or twice monthly intervals; more rapid titration may be appropriate in some patients (refer to topic).</p>
<p>¶ Maximum recommended daily dose of citalopram is generally 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking interacting medications that can increase citalopram levels. For additional information, refer to UpToDate topic review of SSRI pharmacology, administration, and side effects.</p>
<p>Δ Supratherapeutic dosing is not recommended for citalopram because higher doses have been associated with greater risk of QTc prolongation.</p>
◊ Fluvoxamine daily doses &gt;100 mg should be given in two divided doses per day.</div><div id="graphicVersion">Graphic 141578 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
